Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Shareholder Meeting (November 2019)
21 slides from Kazia Therapeutics's shareholder meeting presentation, Nov 13, 2019
Slide 1: Presentation to Annual General Meeting of Shareholders
Presentation to Annual General Meeting of Shareholders Dr James Garner Chief Executive Officer Sydney, NSW 13 November 2019
Slide 2: Agenda: 2019 in Review, Looking Forward
Agenda 2019 in Review Looking Forward
Slide 3: Six ongoing clinical trials across two assets, lead program covers full range of brain cancers
Six ongoing clinical trials across two assets, lead program covers full range of brain cancers Glioblastoma Most common and most aggressive brain tumour Phase II NCT03522298 DIPG Highly aggressive childhood brain tumour Phase I NCT03696355 Brain Metastases Cancer that has spread from any primary tum
Slide 4: Kazia's phase 2 study in newly-diagnosed GBM is ongoing, with new data coming in November 2019
Kazia’s phase 2 study in newly-diagnosed GBM is ongoing, with new data coming in November 2019 Note: timelines are estimated and subject to periodic revision based on recruitment performance and treatment effect Step 1: Dose Optimisation 6 – 24 patients 12 months 20 patients 6 months Step 2: Expansi
Slide 5: The Alliance study in brain metastases is a cutting-edge, multi-drug clinical trial
The Alliance study in brain metastases is a cutting-edge, multi-drug clinical trial Tumour is genetically profiled GDC-0084 entrectinib abemaciclib 150 patients Secondary brain cancer from any primary tumour ‘Precision medicine’ study in which treatment is guided by the specific genetic make-up of e
Slide 6: The St Jude study in DIPG has the potential for breakthrough designation and early approval
The St Jude study in DIPG has the potential for breakthrough designation and early approval Step 1: Dose Escalation 6 – 24 patients 12 patients Step 2: Expansion Cohort All patients with DIPG or high-grade gliomas (2 – 22 years of age), following radiotherapy GDC-0084 given once daily, orally, as mo
Slide 7: Important new preclinical data has also been reported during the year
Important new preclinical data has also been reported during the year References: Duchatel et al. Neuro-Oncology (2019). 21(Suppl. 2):ii68; Ippen et al. Clin Cancer Res. (2019). 25(11):3374-83 DIPG Breast Cancer Brain Metastases
Slide 8: The PI3K class has been further validated by the approval of Novartis' Piqray
The PI3K class has been further validated by the approval of Novartis’ Piqray (alpelisib) FDA Approved July 2014 (blood cancers) [accelerated approval] FDA Approved September 2017 (blood cancers) [accelerated approval] FDA Approved October 2018 (blood cancers) [accelerated approval] ü ü ü Potentiall
Slide 9: Our efforts continue to be recognised in the public sphere
Our efforts continue to be recognised in the public sphere
Slide 10: A range of content, from academic papers to media interviews, helps investors grasp our story
A range of content, from academic papers to media interviews, helps investors grasp our story
Slide 11: The Trans-Tasman Innovation and Growth Award was a powerful recognition of Kazia's achievements
The Trans-Tasman Innovation and Growth Award was a powerful recognition of Kazia’s achievements
Slide 12: These milestones have been achieved with tight operational management and financial economy
These milestones have been achieved with tight operational management and financial economy AU$ million 4.4 5.9 6.9 5.1 4.5 Expense → ← Income G&A % 44.9% 37.8% 44.1% 27.1% 36.0% bar totals = net expenditure 38.0% 4.1
Slide 13: Agenda: 2019 in Review, Looking Forward
Agenda 2019 in Review Looking Forward
Slide 14: From 2020 onwards, GDC-0084 will be known as 'paxalisib'
From 2020 onwards, GDC-0084 will be known as ‘paxalisib’ Internal compound code International Non-proprietary Name (INN) Commercial Brand Name Selected by company once drug begins journey to clinical trials Awarded by WHO, usually around phase 1 / 2 clinical trials Selected by FDA after recommendati
Slide 15: Next step for paxalisib is a pivotal study for registration
Next step for paxalisib is a pivotal study for registration Market Phase 3 Phase 2 Phase 1 Preclinical 4-7 years 8-10 years Paxalisib is here Upcoming SNO data read-out will be a key check-point before committing to phase 3 Kazia expects to share more detail on phase 3 plans early in CY2020, pending
Slide 16: In the meantime, important new data will be presented at the upcoming SNO conference
In the meantime, important new data will be presented at the upcoming SNO conference Phase II Trial in Glioblastoma Phase I Trial in Advanced Glioma poster presentation oral presentation Lead Author: Professor Patrick Wen Dana-Farber Cancer Institute Lead Author: Professor Ben Ellingson UCLA Imaging
Slide 17: Early-stage studies typically provide less mature efficacy endpoints
Early-stage studies such as the ongoing phase 2 typically provide less mature efficacy endpoints Patient-reported outcomes (e.g. pain) Biomarkers (e.g. CA125, PSA, FDG-PET) Tumour Response (i.e. CR, PR, SD, PD) Progression-Free Survival (PFS) Overall Survival (OS) Exploratory Endpoints Never suitabl
Slide 18: Paxalisib data will ultimately be compared against several key benchmarks
GDC-0084 GDC-0084 Temozolomide Temozolomide Paxalisib data will ultimately be compared against several key benchmarks Source: PY Wen et al. Poster Presentation at ASCO (2016); ME Hegi et al. (2008) J Clin Oncol. 26:4189-4199 26% Of patients with a metabolic partial response on FDG-PET 40% Of patient
Slide 19: The partnering market for new oncology drugs is active and driven by emerging data
The partnering market for new oncology drugs is active and driven by emerging data Licensee Licensor Stage Asset(s) Deal Value (US$) Discovery Lipid kinase inhibitors $470M Preclinical Anti-CD38 antibody $275M Preclinical RAS-RAF-MAPK inhibitors $207M Clinical MEK inhibitor $700M Discovery Complemen
Slide 20: The next six months will be an exciting period for Kazia
The next six months will be an exciting period for Kazia, and a crucial inflection point for our programs Note: all milestones are indicative and subject to periodic revision in light of operational factors and emerging data November 2019 Initial interim data from ongoing phase 2 study of paxalisib
Slide 21: Kazia Therapeutics
ee ecee” THERAPEUTICS
Kazia Therapeutics — Shareholder Meeting (November 2019) on 6ix